Hong Jen Chang

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

YFY Biotech Management Co. Ltd. (YFYBM) is a private equity investment firm located in Taipei, Taiwan. Established in 2003, they are subsidiary of the Yuen Foong Yu Group Co. Ltd., founded in 1926 with their core business initially focused on paper manufacturing. YFYBM is the investment manager of biotechnology private equity fund

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

MiCareo, Inc. provides tools for the analysis of rare cells. It circulates tumor cell platform does rare cell isolation and analysis for cancer prognosis, treatment development, and efficacy evaluation. The firm’s product MiSelect starts with whole blood labeled with any fluorescent cell surface antibody or cocktail of multiple antibodies. The company was founded by Perry Schiro and Daniel T. Chiu in 2011 and is headquartered in Taipei, Taiwan.

NeuroSky, Inc. develops biosensor technology services. Its biosensors, biometric algorithms, reference designs, and big data analytics enable leading-edge innovation in mhealth products and services for measuring body and mind performance. The company was founded by Hyung Koo Lee and Jong Jin Lim in 2004 and is headquartered in San Jose, CA.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

Taiwan Global BioFund invests exclusively in life science companies located in Taiwan and US. The fund targets companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, medical services, and medical informatics. It provides financing for seed, early and later stage capital requirements.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

YFY Biotech Management Co. Ltd. (YFYBM) is a private equity investment firm located in Taipei, Taiwan. Established in 2003, they are subsidiary of the Yuen Foong Yu Group Co. Ltd., founded in 1926 with their core business initially focused on paper manufacturing. YFYBM is the investment manager of biotechnology private equity fund

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.

Taiwan Global BioFund invests exclusively in life science companies located in Taiwan and US. The fund targets companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, medical services, and medical informatics. It provides financing for seed, early and later stage capital requirements.

MiCareo, Inc. provides tools for the analysis of rare cells. It circulates tumor cell platform does rare cell isolation and analysis for cancer prognosis, treatment development, and efficacy evaluation. The firm’s product MiSelect starts with whole blood labeled with any fluorescent cell surface antibody or cocktail of multiple antibodies. The company was founded by Perry Schiro and Daniel T. Chiu in 2011 and is headquartered in Taipei, Taiwan.

NeuroSky, Inc. develops biosensor technology services. Its biosensors, biometric algorithms, reference designs, and big data analytics enable leading-edge innovation in mhealth products and services for measuring body and mind performance. The company was founded by Hyung Koo Lee and Jong Jin Lim in 2004 and is headquartered in San Jose, CA.

Taiwan Global BioFund invests exclusively in life science companies located in Taiwan and US. The fund targets companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, medical services, and medical informatics. It provides financing for seed, early and later stage capital requirements.

Taiwan Global BioFund invests exclusively in life science companies located in Taiwan and US. The fund targets companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, medical services, and medical informatics. It provides financing for seed, early and later stage capital requirements.

NeuroSky, Inc. develops biosensor technology services. Its biosensors, biometric algorithms, reference designs, and big data analytics enable leading-edge innovation in mhealth products and services for measuring body and mind performance. The company was founded by Hyung Koo Lee and Jong Jin Lim in 2004 and is headquartered in San Jose, CA.

NeuroSky, Inc. develops biosensor technology services. Its biosensors, biometric algorithms, reference designs, and big data analytics enable leading-edge innovation in mhealth products and services for measuring body and mind performance. The company was founded by Hyung Koo Lee and Jong Jin Lim in 2004 and is headquartered in San Jose, CA.

MiCareo, Inc. provides tools for the analysis of rare cells. It circulates tumor cell platform does rare cell isolation and analysis for cancer prognosis, treatment development, and efficacy evaluation. The firm’s product MiSelect starts with whole blood labeled with any fluorescent cell surface antibody or cocktail of multiple antibodies. The company was founded by Perry Schiro and Daniel T. Chiu in 2011 and is headquartered in Taipei, Taiwan.